PUT/GILEAD SCIENCES/90/0.1/21.06.24 | Market Closed - BOERSE MUENCHEN 19:26:58 07/06/2024 BST | ||
| 2.432 EUR | -0.90% |
|
| Current month | -2.17% | ||
| 1 month | +6.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 2.432 | -0.90% |
| 06/06/24 | 2.454 | +0.33% |
| 05/06/24 | 2.446 | +0.45% |
| 04/06/24 | 2.435 | -1.81% |
| 03/06/24 | 2.48 | -0.24% |
Real-time BOERSE MUENCHEN
Last update June 07, 2024 at 07:26 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | Goldman Sachs |
| WKN | GP9ZN2 |
| ISIN | DE000GP9ZN21 |
| Date issued | 24/07/2023 |
| Strike | 90 $ |
| Maturity | 21/06/2024 (13 Days) |
| Parity | 10 : 1 |
| Emission price | 1.05 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.63 € |
|---|---|
| Lowest since issue | 0.57 € |
| Spread | 0.01 € |
| Spread % | 0.41% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.7
USD
Average target price
82.7
USD
Spread / Average Target
+27.82%
- Stock Market
- Warrants
- Warrant